Last reviewed · How we verify
Loceryl NL + Cosmetic varnish
Amorolfine is a morpholine antifungal that inhibits fungal sterol synthesis by blocking both Δ14-reductase and Δ8-Δ7-isomerase enzymes in the ergosterol biosynthesis pathway.
Amorolfine is a morpholine antifungal that inhibits fungal sterol synthesis by blocking both Δ14-reductase and Δ8→Δ7-isomerase enzymes in the ergosterol biosynthesis pathway. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | Loceryl NL + Cosmetic varnish |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Morpholine antifungal |
| Target | Δ14-steroid reductase and Δ8→Δ7-isomerase (ergosterol biosynthesis pathway) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
By disrupting ergosterol production in fungal cell membranes, amorolfine compromises membrane integrity and function, leading to fungal cell death. The cosmetic varnish formulation provides a protective, occlusive barrier that enhances drug penetration into infected nail tissue while improving cosmetic appearance during treatment.
Approved indications
- Onychomycosis (fungal nail infection)
Common side effects
- Local irritation or burning at application site
- Nail discoloration or discomfort
- Allergic contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loceryl NL + Cosmetic varnish CI brief — competitive landscape report
- Loceryl NL + Cosmetic varnish updates RSS · CI watch RSS
- Galderma R&D portfolio CI